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RSelection Bias in “Prognostic
Impact of Staged Versus
‘One-Time’ Multivessel
Percutaneous Intervention in
Acute Myocardial Infarction”
Kornowski et al. (1) should be commended for attempting to
validate the current guidelines regarding staged versus “one-time”
stenting in the setting of an acute ST-segment elevation myocar-
dial infarction. Their recent article in the Journal was a prespecified
econdary analysis of the HORIZONS-AMI (Harmonizing Out-
omes With Revascularization and Stents in Acute Myocardial
nfarction) cohort.
Given the high likelihood of measured and nonmeasured
aseline differences between the groups who received multivessel
tenting in either a staged or “one-time” fashion, the researchers
ook pains to limit confounding through multivariate and propen-
ity score modeling. Unfortunately, such modeling cannot account
or the patients who had multivessel coronary disease but were
ever included in this analysis because they developed contraindi-
ations (e.g., renal failure or neurological complications) to repeat
ercutaneous coronary intervention (PCI) or died before a second
CI attempt. This survival-based selection bias clearly favors the
taged approach by excluding patients in the HORIZONS-AMI
rial with multivessel disease who received only culprit artery
tenting because they did not survive long enough (or well enough)
o have their other lesions treated. Figures 2 and 3 of their paper
1) corroborated that the majority of deaths in the “one-time”
roup happened within the first few days of the index event.
eanwhile, the median time between first and second PCI events
n the staged group was 30 days later (range 6 to 51 days).
The analysis presented by Kornowski et al. (1) corroborated the
urrent American Heart Association/American College of Cardi-
logy Class III Level of Evidence: B guidelines that “PCI should
ot be performed in a noninfarct artery at the time of primary PCI
n patients without hemodynamic compromise.” Although the
uidelines are clear, there have been discordant, albeit potentially
awed, results in recent published reports regarding this practice
2,3), and it remains more common than might be explained by
ardiogenic shock alone (4). Unfortunately, the selection bias
nherent to the study by Kornowski et al. (1) may have limited its
bility to definitively settle any lingering questions about “one-
ime” multivessel stenting in the setting of an AMI without
emodynamic compromise. A report on the total number of
atients with multivessel coronary disease at the time of primary
ngiography in the HORIZONS-AMI trial and their outcomes
lassified by number of vessels stented (1 vs. 1) and timing
staged vs. “one time”) of their PCI would help us understand how
uch selection bias affected the reported results.*James M. McCabe, MD
Ehrin J. Armstrong, MD
*Brigham and Women’s Hospital
75 Francis Street
Boston, Massachusetts 02115
E-mail: mccabe@aya.yale.edu
doi:10.1016/j.jacc.2011.09.057
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Reply
We thank Drs. McCabe and Armstrong for their valuable comment
in regards to our paper (1). In general, we tend to agree with them but
also want to mention that we clearly stated in the article that despite
the best propensity-controlled analysis and given the risk of residual
confounding, a randomized trial is required to definitively address this
issue. We also agree that the results of patients in the single-treatment
multivessel arm may be “biased” because of peri-procedural compli-
cations; however, as we also pointed out in the article, some of these
procedures may have been instigated by a more complex and lengthy
single procedure, such as contrast nephropathy, which might have
been avoided with a more judiciously staged procedure strategy. Thus,
these data were consistent with the current American Heart Associ-
ation/American College of Cardiology and European Society of
Cardiology guidelines to only treat the infarct artery, pending the
results of a more definitive randomized controlled trial. Finally, we are
preparing a paper about the effects of multivessel versus single-vessel
disease, the results of which are forthcoming.
*Ran Kornowski, MD
Gregg W. Stone, MD
*Rabin Medical Center, Petach Tikva
Tel Aviv University
Jabotinsky Road
Retach-Tikva, Petach Tikva 49100
Israel
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Is Renal Function-Based Contrast
Dosing of Radiographic Contrast
Media in Patients Undergoing
Percutaneous Coronary
Intervention Sufficient to
Delineate Safe Limits of
Contrast Dose?
The observational study by Gurm et al. (1) showed that the ratio
of contrast volume to creatinine clearance (CV/CCC) is a simple
tool that can help reduce the risk of contrast-induced nephropathy
(CIN) in patients undergoing percutaneous coronary intervention.
The most important preventive measure is reducing the CV, and
this article focused on defining the dose range that would optimize
patient safety. However, the proposed formula has several short-
comings in high-risk patients.
Cigarroa et al. (2) in 1989 reported an empiric formula, 5weight
(kg)/serum creatinine, that is known as the maximal acceptable
contrast dose (MACD) for calculating the maximal dose of contrast
that can be given safely. They validated their formula in 115 patients
with serum creatinine 1.8 mg/dl undergoing coronary angiography
nd showed a rise in the incidence of CIN from 2% to 21% if CV
xceeded the maximum recommended by MACD. Their formula is
ommonly used in catheterization laboratories but suffers from signif-
cant drawbacks. Many patients will develop CIN even when MACD
s not exceeded. This formula does not specify a different safe dose
imit for high-risk patients such as those with diabetes, heart failure,
nemia, and cardiogenic shock. Cigarroa et al. (2) showed a rise in
CIN from 2% to 6% in patients with diabetes receiving CV within
MACD dose limits and a rise in CIN from 21% to 38% in patients
with diabetes if CV exceeded MACD. Contrast dose recommended
by CV/CCC is better than MACD at predicting CIN because
CV/CCC formula takes age and sex into consideration in addition to
the factors used in the MACD formula. However CV/CCC does not
consider the high-risk features noted earlier.
Gurm et al. (1) concluded that a “contrast dose on the basis of
CC with a planned CV restricted to2 CCC might be valuable
in reducing the risk of CdIN.” In their overall population, this CV was
associated with an incidence of CIN of 2%. However, this CV is
ssociated with an incidence of CIN of 4% in patients undergoing
ercutaneous coronary intervention for ST-segment elevation myo-
ardial infarction (Fig. 3), 23% for patients in cardiogenic shock (Fig.), and 4% to 6.5% in patients with a glomerular filtration rate 60
l/min (Fig. 4). Clearly, for these high-risk patients, another formula
s necessary to reduce the risk of CIN.
Nishant Kalra, MD
aul Fenster, MD
Sarver Heart Center
niversity of Arizona
501 North Campbell Avenue, Room 4143
ucson, Arizona 85724-5037
doi:10.1016/j.jacc.2011.09.060
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Reply
We welcome Drs. Kalra and Fenster’s interest in our work
delineating the association between renal function–based contrast
dose and the risk of renal complications in patients undergoing
percutaneous coronary intervention (1). They argued that in
high-risk patients, and especially among patients with cardiogenic
shock, the incidence of contrast-induced nephropathy (CIN) is
unacceptably high, even when the ratio of contrast volume to
creatinine clearance is 2, and invoked the need for “another
formula to reduce the risk of CIN.”
The goal of our study was to define a simple strategy for contrast
dosing, and as our study highlighted, there was no dose of contrast
that is absolutely free of risk. The risk of renal dysfunction is
determined by the baseline clinical characteristics of the patients,
and in high-risk patients, the risk of CIN will be higher than that
in lower-risk patients.
Currently, any deterioration of renal function following contrast
administration is classified as CIN; however, some of these events
are secondary to cholesterol embolism, and an additional unknown
number of events, especially in cardiogenic shock, might be
secondary to acute tubular necrosis. This may be one reason why it
has been difficult to develop a simple formula for defining contrast
dose in this subgroup of patients.
The relative contribution of contrast media to renal dysfunction
in patients with shock remains unknown. Indeed, in the SHOCK
(Should We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock) trial, the risk of renal failure was higher in
patients in the medical arm compared with patients in the
revascularization arm (2).
We agree that better strategies to reduce the incidence of renal
dysfunction in these patients are urgently warranted. However, it is
likely that these efforts will need to be multidimensional, and
measures in addition to minimization of contrast will need to be
explored. It may be possible to develop another formula that would
help better define the safe limit of contrast for these high-risk
patients, but in the absence of such a formula, creatinine clearance–
based contrast dosing appears to be a simple strategy that may
